BIOMAT Database Logo BIOMAT Database Logo

A cystic fibrosis mutation associated with mild lung disease. 1995

K H Gan, and H J Veeze, and A M van den Ouweland, and D J Halley, and H Scheffer, and A van der Hout, and S E Overbeek, and J C de Jongste, and W Bakker, and H G Heijerman
Department of Pulmonology, Leyenburg Hospital, The Hague, The Netherlands.

BACKGROUND Cystic fibrosis is the most common lethal autosomal recessive disorder among whites. Among Dutch patients with cystic fibrosis, delta F508 is the most common mutation and A455E the second most common mutation of the cystic fibrosis transmembrane conductance regulator gene on chromosome 7. A455E is associated with preserved pancreatic function and residual secretion of chloride across membranes. We investigated whether it is also associated with less severe pulmonary disease in patients with cystic fibrosis. METHODS A total of 33 patients with compound heterozygosity for the A455E mutation were matched according to age and sex with patients who were homozygous for the delta F508 mutation. The pairs were analyzed with respect to the following outcome variables: age at diagnosis, pulmonary-function values, and the frequency of pseudomonas colonization, pancreatic sufficiency, and diabetes mellitus. RESULTS Cystic fibrosis was diagnosed at a later age in the patients with the A455E mutation than in the delta F508 homozygotes (mean age at diagnosis, 15.0 vs. 3.1 years; P < 0.001). Fewer patients with the A455E mutation had pancreatic insufficiency (21.2 percent vs. 93.9 percent, P < 0.001), and none had diabetes mellitus (0 percent vs. 27.3 percent, P = 0.004). Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were significantly higher in the patients with the A455E mutation (mean FEV1, 73.9 percent of the predicted value vs. 54.3 percent of the predicted value; P = 0.002; mean FVC, 88.7 percent of the predicted value vs. 76.3 percent of the predicted value; P = 0.04). Fewer patients with the A455E mutation were colonized with Pseudomonas aeruginosa (33.3 percent vs. 60.6 percent, P = 0.02). CONCLUSIONS A455E is a common mutation causing cystic fibrosis in the Netherlands. Although several mutations are known to be associated with less severe pancreatic disease, our findings demonstrate a correlation between the A455E mutation and mild pulmonary disease. Because mortality in this disease depends primarily on the progression of pulmonary disease, patients with the A455E mutation have a better prognosis than patients who are homozygous for the delta F508 mutation.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D008565 Membrane Proteins Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors. Cell Membrane Protein,Cell Membrane Proteins,Cell Surface Protein,Cell Surface Proteins,Integral Membrane Proteins,Membrane-Associated Protein,Surface Protein,Surface Proteins,Integral Membrane Protein,Membrane Protein,Membrane-Associated Proteins,Membrane Associated Protein,Membrane Associated Proteins,Membrane Protein, Cell,Membrane Protein, Integral,Membrane Proteins, Integral,Protein, Cell Membrane,Protein, Cell Surface,Protein, Integral Membrane,Protein, Membrane,Protein, Membrane-Associated,Protein, Surface,Proteins, Cell Membrane,Proteins, Cell Surface,Proteins, Integral Membrane,Proteins, Membrane,Proteins, Membrane-Associated,Proteins, Surface,Surface Protein, Cell
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009426 Netherlands Country located in EUROPE. It is bordered by the NORTH SEA, BELGIUM, and GERMANY. Constituent areas are Aruba, Curacao, and Sint Maarten, formerly included in the NETHERLANDS ANTILLES. Holland,Kingdom of the Netherlands
D012129 Respiratory Function Tests Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc. Lung Function Tests,Pulmonary Function Tests,Function Test, Pulmonary,Function Tests, Pulmonary,Pulmonary Function Test,Test, Pulmonary Function,Tests, Pulmonary Function,Function Test, Lung,Function Test, Respiratory,Function Tests, Lung,Function Tests, Respiratory,Lung Function Test,Respiratory Function Test,Test, Lung Function,Test, Respiratory Function,Tests, Lung Function,Tests, Respiratory Function
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002897 Chromosomes, Human, Pair 7 A specific pair of GROUP C CHROMOSOMES of the human chromosome classification. Chromosome 7
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases

Related Publications

K H Gan, and H J Veeze, and A M van den Ouweland, and D J Halley, and H Scheffer, and A van der Hout, and S E Overbeek, and J C de Jongste, and W Bakker, and H G Heijerman
A cystic fibrosis mutation associated with mild lung disease.
December 1995, The New England journal of medicine,
K H Gan, and H J Veeze, and A M van den Ouweland, and D J Halley, and H Scheffer, and A van der Hout, and S E Overbeek, and J C de Jongste, and W Bakker, and H G Heijerman
Novel cystic fibrosis mutation associated with mild disease in Cypriot patients.
May 1994, Human genetics,
K H Gan, and H J Veeze, and A M van den Ouweland, and D J Halley, and H Scheffer, and A van der Hout, and S E Overbeek, and J C de Jongste, and W Bakker, and H G Heijerman
Mild Cystic Fibrosis Lung Disease Is Associated with Bacterial Community Stability.
September 2021, Microbiology spectrum,
K H Gan, and H J Veeze, and A M van den Ouweland, and D J Halley, and H Scheffer, and A van der Hout, and S E Overbeek, and J C de Jongste, and W Bakker, and H G Heijerman
Lung T1 MRI assessments in children with mild cystic fibrosis lung disease.
May 2024, Pediatric pulmonology,
K H Gan, and H J Veeze, and A M van den Ouweland, and D J Halley, and H Scheffer, and A van der Hout, and S E Overbeek, and J C de Jongste, and W Bakker, and H G Heijerman
Association of pancreatic adenocarcinoma, mild lung disease, and delta F508 mutation in a cystic fibrosis patient.
October 1994, Clinical chemistry,
K H Gan, and H J Veeze, and A M van den Ouweland, and D J Halley, and H Scheffer, and A van der Hout, and S E Overbeek, and J C de Jongste, and W Bakker, and H G Heijerman
Quantitative air-trapping analysis in children with mild cystic fibrosis lung disease.
November 2004, Pediatric pulmonology,
K H Gan, and H J Veeze, and A M van den Ouweland, and D J Halley, and H Scheffer, and A van der Hout, and S E Overbeek, and J C de Jongste, and W Bakker, and H G Heijerman
Assessment of fitness in patients with cystic fibrosis and mild lung disease.
May 1997, Thorax,
K H Gan, and H J Veeze, and A M van den Ouweland, and D J Halley, and H Scheffer, and A van der Hout, and S E Overbeek, and J C de Jongste, and W Bakker, and H G Heijerman
BEATing cystic fibrosis: more on rhDNase and mild lung disease.
October 2004, Pediatric pulmonology,
K H Gan, and H J Veeze, and A M van den Ouweland, and D J Halley, and H Scheffer, and A van der Hout, and S E Overbeek, and J C de Jongste, and W Bakker, and H G Heijerman
Ivacaftor in severe cystic fibrosis lung disease and a G551D mutation.
December 2013, Respirology case reports,
K H Gan, and H J Veeze, and A M van den Ouweland, and D J Halley, and H Scheffer, and A van der Hout, and S E Overbeek, and J C de Jongste, and W Bakker, and H G Heijerman
Lung infections associated with cystic fibrosis.
April 2002, Clinical microbiology reviews,
Copied contents to your clipboard!